TATAA Biocenter Partners with SimplicityBio
News Oct 26, 2016
TATAA Biocenter has partnered with SimplicityBio to offer complete solutions for biomarker discovery, signature optimization and validation. The partnership offers a complete solution comprising biomarker discovery, assay and protocol optimization, analytical validation, standardization, and clinical validation leading to robust and reliable biomarker signatures for diagnostics, prognostics and theranostics. Platforms include microarrays, qPCR, dPCR and NGS and virtually any kind of biomarkers with emphasis on mRNA, microRNA, lncRNA, DNA (SNP, CNV, methylation, cfDNA), protein and circulating tumor cells.
“Leveraging on our experience of quality control and standardization of molecular analyses we design experimental protocols and generate data of highest quality for our clients. Combining our data with first class biomarker analyses provided by SimplicityBio, we provide our clients with complete solutions” says Mikael Kubista, President of TATAA Biocenter.
"We’re always looking to partner with innovative companies that are true leaders in the genomic services industry, and TATAA Biocenter is exactly that. TATAA Biocenter supports clients with design and validation of assays and generates genomic data of highest quality based on their accredited pipelines. Those data are perfect inputs for our biomarker discovery and modelling pipelines” said Dr. Matthew Hall CSO of SimplicityBio. Together we offer our clients the most powerful platform for biomarker discover, validation and confirmation currently available.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE
8th Edition of International Conference and Exhibition on Separation Techniques
Jul 29 - Jul 30, 2019